AUTL
Autolus Therapeutics plc
NASDAQ · Healthcare · Biotechnology · GB
$2.24
−2.18%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 117.4M | 75.6M | 10.1M | 1.7M | 6.2M |
| Cost of Revenue | 99.0M | 96.6M | 141.0M | — | — |
| Gross Profit | 18.4M | (21.0M) | (130.9M) | 1.7M | 6.2M |
| Operating Expenses | |||||
| R&D Expense | 112.6M | 128.6M | 158.1M | 130.5M | 117.4M |
| SG&A Expense | 153.1M | 131.8M | — | 46.7M | 31.9M |
| General & Admin Expense | 117.4M | — | — | 46.7M | 31.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.00 | — | (47.6M) | 4.2M | (166.0K) |
| Total Operating Expenses | 265.7M | 260.4M | 110.5M | 181.4M | 149.1M |
| Cost and Expenses | 364.7M | 357.0M | 251.5M | 181.4M | 149.1M |
| Operating Income (EBIT) | (247.3M) | (281.4M) | (241.4M) | (179.7M) | (142.9M) |
| Non-Operating | |||||
| Interest Income | 12.0M | 19.0M | 32.4M | 13.5M | 1.7M |
| Interest Expense | 47.1M | 36.8M | 9.3M | 45.1M | 8.9M |
| Net Interest Income | (35.2M) | (17.7M) | 23.1M | (31.6M) | (7.2M) |
| Other Non-Op Income/Expense | (32.0M) | (15.4M) | 22.3M | (28.7M) | (5.7M) |
| Non-Operating Income (excl Interest) | (15.1M) | (21.3M) | (637.0K) | (16.4M) | (3.2M) |
| EBT (Pre-Tax Income) | (279.3M) | (296.8M) | (219.1M) | (208.4M) | (148.6M) |
| Income Tax Expense | 677.3K | (8.6M) | 1.5M | (19.0K) | 272.0K |
| Bottom Line | |||||
| Net Income | (280.0M) | (288.2M) | (220.7M) | (208.4M) | (148.8M) |
| Earnings from Cont. Ops | (280.0M) | (288.2M) | (220.7M) | (208.4M) | (148.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (280.0M) | (288.2M) | (220.7M) | (208.4M) | (148.8M) |
| Per Share | |||||
| Basic EPS | ($1.06) | ($1.08) | ($0.87) | ($1.20) | ($1.57) |
| Diluted EPS | ($1.06) | ($1.08) | ($0.87) | ($1.20) | ($1.57) |
| Revenue Per Share | $0.44 | $0.28 | $0.04 | $0.01 | $0.07 |
| Shares | |||||
| Basic Shares Outstanding | 266.2M | 266.1M | 255.2M | 173.9M | 95.0M |
| Diluted Shares Outstanding | 266.2M | 266.1M | 255.2M | 173.9M | 95.0M |
| Profitability Metrics | |||||
| EBITDA | (221.4M) | (250.3M) | (233.1M) | (156.8M) | (132.2M) |
| D&A | 10.8M | 9.8M | 7.7M | 6.6M | 7.4M |
| EBIT | (232.2M) | (260.1M) | (240.8M) | (163.3M) | (139.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026